LITT for ultra-early GBM recurrence within 1 week of pre-radiation planning

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Glioblastoma remains highly aggressive even after initial surgery and chemoradiation. In many patients, a focal tumor recurrence appears between the first postoperative MRI and the start of radiotherapy, which is linked to poorer survival. The trial investigates using Laser Interstitial Thermal Therapy (LITT) to ablate this ultra-early recurrence within a tight 1-week window before adjuvant therapy, aiming to avoid delaying treatment and potentially improve outcomes. LITT is already used for similar brain lesions and may also sensitize tumors to subsequent radiotherapy and chemotherapy. This interventional study will assess feasibility, safety, and potential plan for integration into standard care without prolonging the overall treatment timeline.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
* ≥18 years of age
* CRET
* Karnofsky Performance Status (KPS) ≥70
* No contra-indication for radio-chemotherapy
* Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern
* Able to provide informed consent
* No contra-indication for LITT
* No pregnancy or active breast-feeding
* No known coagulopathy independent of medication
* No dissemination or multifocal disease
* Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.

Exclusion Criteria:

Where it's running

• Dep. of Neurosurgery, Bern University Hospital
  Bern, Switzerland Recruiting

Study contacts

• Principal investigator: Philippe Schucht, MD — Inselspital Bern, Department of Neurosurgery
• Study coordinator: Philippe Schucht, MD
• Email: philippe.schucht@insel.ch
• Phone: +41 31 632 00 14

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Targeted radioligand therapy for recurrent glioblastoma with Lu-177 XT771

  This early-phase study tests whether a radiolabeled medicine (Lu-177 XT771) delivered directly into the tumor cavity is safe and tolerable for adults with recurrent glioblastoma.

  Recruiting at 2 sites Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07648823

• Personalized Targeted Glioblastoma Therapies Guided by Ex Vivo Drug Screening

  This trial tests whether using a patient’s own tumor cells to screen drugs can guide a personalized treatment plan for people with newly diagnosed glioblastoma undergoing short-course radiotherapy.

  Recruiting Medical University of Vienna · Vienna, State of Vienna · NCT07627334

• Combined intracranial and intravenous NK cell therapy for malignant brain tumors

  This trial will test whether giving adults with recurrent malignant brain tumors their own expanded and activated natural killer (NK) cells into the tumor site and into the bloodstream is safe and feasible.

  Recruiting at 3 sites Peking University Third Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07552233

• Preventive intrathecal thiotepa with standard chemoradiation for high‑risk glioblastoma

  This trial tests whether adding six weekly intrathecal injections of thiotepa to standard chemoradiation can lower leptomeningeal spread and improve outcomes for adults with newly diagnosed GBM that contacts the subventricular zone or had ventricular entry during surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07511725

• Local targeted alpha therapy using 225Ac‑DOTA‑SP for newly diagnosed WHO grade 3–4 glioma

  This trial tests a local peptide‑guided alpha‑particle treatment (225Ac‑DOTA‑SP) in adults 18–80 with newly diagnosed WHO grade 3–4 glioma after initial surgery and radiochemotherapy to see if it safely targets residual tumor and improves local control.

  Recruiting at 2 sites Medical University of Warsaw · Warsaw, Poland and 1 other locations · NCT07488754

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.